FuzzyBot: Importing a new version from external source

2024-03-11T10:35:32Z

Importing a new version from external source

New page

=== Polycystic ovarian syndrome ===
In those with polycystic ovarian syndrome (PCOS), tentative evidence shows that metformin use increases the rate of live births. This includes in those who have not been able to get pregnant with clomiphene. Metformin does not appear to change the risk of miscarriage. A number of other benefits have also been found both during pregnancy and in nonpregnant women with PCOS. In an updated Cochrane (2020) review on metformin versus placebo/no treatment before or during [[In vitro fertilisation|IVF/ICSI]] in women with PCOS no conclusive evidence of improved live birth rates was found. In long [[Gonadotropin-releasing hormone agonist|GnRH-agonist]] protocols there was uncertainty in the evidence of improved live birth rates but there could be increases in clinical pregnancy rate. In short [[GNRH antagonist|GnRH-antagonist]] protocols metformin may reduce live birth rates with uncertainty on its effect on clinical pregnancy rate. Metformin may result in a reduction of [[Ovarian hyperstimulation syndrome|OHSS]] but could come with a greater frequency of side effects. There was uncertainty as to metformin's impact on miscarriage. The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women.

Translations:Metformin/17/en - Revision history

FuzzyBot: Importing a new version from external source